Mathew S. Maurer

Gene Silencer Therapy in Transthyretin Amyloid Cardiomyopathy

Importance: Gene-silencing therapies reduce hepatic transthyretin (TTR) production and have been evaluated in phase 3 trials in TTR amyloid cardiomyopathy (ATTR-CM). However, differences in trial design and background therapies have limited assessment of the overall treatment eff...